Macrophage Iron, Hepcidin, and Atherosclerotic Plaque Stability
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Hepcidin has emerged as the key hormone in the regulation of iron balance and recycling. Elevated levels increase iron in macrophages and inhibit gastrointestinal iron uptake. The physiology of hepcidin suggests an additional mechanism by which iron depletion could protect against atherosclerotic lesion progression. Without hepcidin, macrophages retain less iron. Very low hepcidin levels occur in iron deficiency anemia and also in homozygous hemochromatosis. There is defective retention of iron in macrophages in hemochromatosis and also evidently no increase in atherosclerosis in this disorder. In normal subjects with intact hepcidin responses, atherosclerotic plaque has been reported to have roughly an order of magnitude higher iron concentration than that in healthy arterial wall. Hepcidin may promote plaque destabilization by preventing iron mobilization from macrophages within atherosclerotic lesions; the absence of this mobilization may result in increased cellular iron loads, lipid peroxidation, and progression to foam cells. Marked downregulation of hepcidin (e.g., by induction of iron deficiency anemia) could accelerate iron loss from intralesional macrophages. It is proposed that the minimally proatherogenic level of hepcidin is near the low levels associated with iron deficiency anemia or homozygous hemochromatosis. Induced iron deficiency anemia intensely mobilizes macrophage iron throughout the body to support erythropoiesis. Macrophage iron in the interior of atherosclerotic plaques is not exempt from this process. Decreases in both intralesional iron and lesion size by systemic iron reduction have been shown in animal studies. It remains to be confirmed in humans that a period of systemic iron depletion can decrease lesion size and increase lesion stability as demonstrated in animal studies. The proposed effects of hepcidin and iron in plaque progression offer an explanation of the paradox of no increase in atherosclerosis in patients with hemochromatosis despite a key role of iron in atherogenesis in normal subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“Lower levels are associated with anemia, hypoxia, iron deficiency, and hereditary hemochromatosis (24, 26, 27, 32).”
BackgroundRidker, P. M., Rifai, N., Stampfer, M. J., & Hennekens, C. H. (2000) · Circulation · doi:10.1161/01.cir.101.15.1767 · Cited by 2,429 · cited 4×
“How IL-6 might act to increase MI risk is not established (71, 73).”
BackgroundInfluentialNicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A., & Vaulont, S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215686 · Cited by 1,214 · cited 1×
“Hepcidin mRNA levels also fall substantially within hours following phlebotomy (33).”
BackgroundHeme oxygenase 1 is required for mammalian iron reutilization
Poss, K. D., & Tonegawa, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10919 · Cited by 1,016
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Self-citationRegulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756 · cited 1×
“Lower levels are associated with anemia, hypoxia, iron deficiency, and hereditary hemochromatosis (24, 26, 27, 32).”
BackgroundSmith, C., Mitchinson, M. J., Aruoma, O. I., & Halliwell, B. (1992) · Biochemical Journal · doi:10.1042/bj2860901 · Cited by 455 · cited 1×
“(35) provided indirect support for the iron hypothesis in a 1992 study that demonstrated the presence of catalytic iron in material taken from human atherosclerotic lesions.”
BackgroundHepcidin—a regulator of intestinal iron absorption and iron recycling by macrophages
GANZ, T. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.08.020 · Cited by 393
Iron imports. IV. Hepcidin and regulation of body iron metabolism
Ganz, T., & Nemeth, E. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00412.2005 · Cited by 347
Stadler, N., Lindner, R. A., & Davies, M. J. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000124892.90999.cb · Cited by 310 · cited 2×
“Davies and colleagues (17) used the minimally disruptive techniques of electron paramagnetic resonance (EPR) spectroscopy and inductively coupled plasma mass spectroscopy (ICPMS) to quantify iron in ex vivo carotid lesions and in healthy human arteries.”
BackgroundMethodIron Chelation Improves Endothelial Function in Patients With Coronary Artery Disease
Duffy, S. J., Biegelsen, E. S., Holbrook, M., Russell, J. D., Gokce, N., Keaney, J. F., & Vita, J. A. (2001) · Circulation · doi:10.1161/01.cir.103.23.2799 · Cited by 271
Theurl, I., Mattle, V., Seifert, M., Mariani, M., Marth, C., & Weiss, G. (2006) · Blood · doi:10.1182/blood-2005-08-3364 · Cited by 188
Iron-Deficient Diet Reduces Atherosclerotic Lesions in ApoE-Deficient Mice
Lee, T.-S., Shiao, M.-S., Pan, C.-C., & Chau, L.-Y. (1999) · Circulation · doi:10.1161/01.cir.99.9.1222 · Cited by 179 · cited 4×
“Interruption of iron acquisition and storage in plaque macrophages by iron restriction or iron chelation inhibit lesion initiation and progression (13, 45).”
BackgroundInfluentialHepcidin expression and iron transport in alveolar macrophages
Nguyen, N.-B., Callaghan, K. D., Ghio, A. J., Haile, D. J., & Yang, F. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00484.2005 · Cited by 143 · cited 1×
“Lower levels are associated with anemia, hypoxia, iron deficiency, and hereditary hemochromatosis (24, 26, 27, 32).”
BackgroundMinqin, R., Rajendran, R., Pan, N., Kwong-Huat Tan, B., Ong, W.-Y., Watt, F., & Halliwell, B. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.01.008 · Cited by 100 · cited 2×
“Interruption of iron acquisition and storage in plaque macrophages by iron restriction or iron chelation inhibit lesion initiation and progression (13, 45).”
BackgroundThe iron hypothesis of atherosclerosis and its clinical impact
Yuan, X., & Li, W. (2003) · Annals of Medicine · doi:10.1080/07853890310016342 · Cited by 93
Iron and Atherosclerosis: Inhibition by the Iron Chelator Deferiprone (L1)
Matthews, A. J., Vercellotti, G. M., Menchaca, H. J., Bloch, P. H. S., Michalek, V. N., Marker, P. H., Murar, J., & Buchwald, H. (1997) · Journal of Surgical Research · doi:10.1006/jsre.1997.5180 · Cited by 68
Yuan, X. M. (1999) · Free Radical Research · doi:10.1080/10715769900300241 · Cited by 59
Stanley, N., Stadler, N., Woods, A. A., Bannon, P. G., & Davies, M. J. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.12.031 · Cited by 51 · cited 1×
“In a later study (47), iron levels in human atherosclerotic plaque correlated positively and strongly with multiple markers of protein oxidation but not with markers of lipid oxidation.”
BackgroundLi, L., & Frei, B. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000245820.34238.da · Cited by 49
A nuclear microscopy study of trace elements Ca, Fe, Zn and Cu in atherosclerosis
Watt, F., Rajendran, R., Ren, M. Q., Tan, B. K. H., & Halliwell, B. (2006) · Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms · doi:10.1016/j.nimb.2006.03.073 · Cited by 48 · cited 1×
“The findings of Watt and colleagues (43) and of Chau and colleagues (14, 45) confirm that plaque macrophage iron can be mobilized by dietary iron restriction, phlebotomy, or iron chelation.”
BackgroundStored Iron and Vascular Reactivity
Sullivan, J. L. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000174124.20147.22 · Cited by 41
Self-citationMisconceptions in the debate on the iron hypothesis
Sullivan, J. L. (2001) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(00)00142-x · Cited by 27 · cited 1×
“The idea, although not yet fully tested and continually debated over the last 25 years (6), has achieved standing as a plausible and testable hypothesis (7– 19).”
BackgroundSelf-citationIron Chelation and Vascular Function: In Search of the Mechanisms
Ferrara, D. E., & Taylor, W. R. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000189303.45609.1f · Cited by 21
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Risks of Copper and Iron Toxicity during Aging in Humans
Brewer, G. J. (2010) · Chemical Research in Toxicology · doi:10.1021/tx900338d · Cited by 395
Iron Sequestration and Anemia of Inflammation
Ganz, T., & Nemeth, E. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.06.001 · Cited by 361
Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target
Dongiovanni, P., Fracanzani, A. L., Fargion, S., & Valenti, L. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.008 · Cited by 362
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Metadata
- Authors
- Sullivan, J. L.
- Venue
- Experimental Biology and Medicine
- Publisher
- Frontiers Media SA
- Published
- 2007-09
- Volume
- 232
- Issue
- 8
- Pages
- 1014-1020
- ISSN
- 0071-3384 (ISSN-L)
- 1535-3702
- 1535-3699
- OpenAlex
- W2015048206
- Cited by
- 144
- References
- 24
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.